Novartis to Buy The Medicines Co. for USD 9.7 Billion

Written by Haley Alber

et|icon_calendar|

November 25, 2019

et|icon_grid-3×3|

Swiss pharmaceutical company Novartis AG (NYSE: NVS) on Sunday said it will buy cholesterol-drug maker The Medicines Company (NASDAQ: MDCO) for USD 9.7 Billion. Shares of The Medicines Company shot up about 22% following the news while Novartis’ stock price remained about flat.

Novartis will acquire Medicines Company for USD 85.00 per share in cash, valuing the company at approximately USD 9.7 Billion.

The deal, expected to close in the first quarter of 2020, will allow Novartis to get its hands on inclisiran, a treatment to lower bad cholesterol. The Medicines Company expects to file regulatory submissions for the drug in the U.S. in the fourth quarter of 2019 and in Europe in the first quarter of 2020.

Recently, The Medicines Company announced data from its clinical trial involving 3,600 patients. According to results from the trial, inclisiran “demonstrated potent and durable” bad cholesterol reduction while remaining safe and tolerable.

Promising data surrounding inclisiran had sent Medicines Company’s stock up around 200% this year, even before rumors of a buyout hit full swing last week.

“This transformational, new investigational medicine has the potential to meaningfully address one of the largest areas of underserved patient need,” said Marie-France Tschudin, President of Novartis Pharmaceuticals. “We believe our strong capabilities and global footprint can help drive broad worldwide access to this much needed treatment.”

The acquisition is expected to “modestly” dilute core EPS versus a no deal scenario during the next few years as Novartis invests for a successful launch of inclisiran.

Stock price

DAY LOW/HIGH

52 week low/high

Comparables

Related Articles

Sanofi Acquires Synthrox for USD 2.5 Billion

Sanofi Acquires Synthrox for USD 2.5 Billion

Healthcare & Biotechs0 Comments Sanofi (NASDAQ: SNY) announced on Monday that it has acquired Synthorx (NASDAQ: THOR) for USD 2.5 Billion to boost its immuno-oncology pipeline. Synthorx shares surged by 169% at the open on Monday. Synthorx is...

Planet Fitness (NYSE: PLNT) Jumps After Sales Beat Expectations

Planet Fitness (NYSE: PLNT) Jumps After Sales Beat Expectations

Healthcare & Biotechs0 Comments Planet Fitness, Inc. (NYSE: PLNT) stock jumped about 10% after the franchisee and operator of fitness centers reported financial results for its third quarter ended September 30, 2019.  Third Quarter Fiscal...

J&J Says 15 Tests Indicate No Asbestos in Baby Powder

J&J Says 15 Tests Indicate No Asbestos in Baby Powder

Healthcare & Biotechs0 Comments Shares of Johnson & Johnson (NYSE: JNJ) opened more than 3% higher on Wednesday after the company reported that 15 new tests from the same bottle of Johnson’s Baby Powder previously tested by the U.S. Food...

Comments

Leave a Reply

avatar
  Subscribe  
Notify of